NURIX THERAPEUTICS, INC. Defined Contribution Plan, Cost
NURIX THERAPEUTICS, INC. (NRIX) reported Defined Contribution Plan, Cost of $400.00 thousand for the 3-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. defined contribution plan, cost for the quarter ending 2026-05-31 was $400.00K, a 20.00% decline year-over-year.
- NURIX THERAPEUTICS, INC. defined contribution plan, cost for the quarter ending 2026-02-28 was $500.00K, a 0.00% change year-over-year.
- NURIX THERAPEUTICS, INC. defined contribution plan, cost for the quarter ending 2025-11-30 was $100.00K, a 0.00% change year-over-year.
- NURIX THERAPEUTICS, INC. defined contribution plan, cost for the quarter ending 2025-08-31 was $100.00K, a 0.00% change year-over-year.
- NURIX THERAPEUTICS, INC. defined contribution plan, cost for fiscal 2025 was $1.20M, a 33.33% increase from fiscal 2024.
- NURIX THERAPEUTICS, INC. defined contribution plan, cost for fiscal 2024 was $900.00K, a 10.00% decline from fiscal 2023.
- NURIX THERAPEUTICS, INC. defined contribution plan, cost for fiscal 2023 was $1.00M, a 11.11% increase from fiscal 2022.
- NURIX THERAPEUTICS, INC. defined contribution plan, cost for fiscal 2022 was $900.00K.
| Period end | Defined Contribution Plan, Cost 3 month | Defined Contribution Plan, Cost 6 month | Defined Contribution Plan, Cost 9 month | Defined Contribution Plan, Cost 12 month |
|---|---|---|---|---|
| 2026-05-31 | $400.00K 10-Q · filed 2026-07-09 | $1.00M 10-Q · filed 2026-07-09 | $1.00M derived: sum of 3 quarters · filed 2026-07-09 | $1.10M derived: sum of 4 quarters · filed 2026-07-09 |
| 2026-02-28 | $500.00K 10-Q · filed 2026-04-08 | $600.00K derived: sum of 2 quarters · filed 2026-04-08 | $700.00K derived: sum of 3 quarters · filed 2026-04-08 | $1.20M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-11-30 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $200.00K derived: sum of 2 quarters · filed 2026-01-28 | $700.00K derived: sum of 3 quarters · filed 2026-07-09 | $1.20M 10-K · filed 2026-01-28 |
| 2025-08-31 | $100.00K 10-Q · filed 2025-10-09 | $600.00K derived: sum of 2 quarters · filed 2026-07-09 | $1.10M 10-Q · filed 2025-10-09 | $1.20M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-05-31 | $500.00K 10-Q · filed 2026-07-09 | $1.00M 10-Q · filed 2026-07-09 | $1.10M derived: sum of 3 quarters · filed 2026-07-09 | $1.20M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-02-28 | $500.00K 10-Q · filed 2026-04-08 | $600.00K derived: sum of 2 quarters · filed 2026-04-08 | $700.00K derived: sum of 3 quarters · filed 2026-04-08 | $1.10M derived: sum of 4 quarters · filed 2026-04-08 |
| 2024-11-30 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $200.00K derived: sum of 2 quarters · filed 2026-01-28 | $600.00K derived: sum of 3 quarters · filed 2026-01-28 | $900.00K 10-K · filed 2026-01-28 |
| 2024-08-31 | $100.00K 10-Q · filed 2025-10-09 | $500.00K derived: sum of 2 quarters · filed 2025-10-09 | $800.00K 10-Q · filed 2025-10-09 | |
| 2024-05-31 | $400.00K 10-Q · filed 2025-07-09 | $800.00K 10-Q · filed 2025-07-09 | ||
| 2024-02-29 | $400.00K 10-Q · filed 2025-04-08 | |||
| 2023-11-30 | $1.00M 10-K · filed 2026-01-28 | |||
| 2022-11-30 | $900.00K 10-K · filed 2025-01-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |